INAB IN8BIO INC

IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference

IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference

NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 at 1:30 pm ET.

The H.C. Wainwright presentation will be available live and as a replay on IN8bio’s website at .

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio is initiating INB-400, a company-sponsored Phase 2 clinical trial in newly diagnosed glioblastoma following IND clearance in late 2022. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit .

Company Contact:

IN8bio, Inc.

Patrick McCall

+ 1 646.600.6GDT (6438)

Investors & Media Contact:

Argot Partners



EN
21/02/2023

Underlying

INABIN8BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IN8BIO INC

 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Reports Third Quarter 2025 Financial Results and Recent Busines...

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine release, highlighting its potential to achieve deep B cell depletion with an improved safety profileExpanded Phase 1 INB-100 trial to The James Comprehensive Cancer Center at The Ohio State University, supporting faster enrollment to complete the Phase 1 expansion cohortContinued to advance IN8bio’s proprietary γ...

November 6, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohi...

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State University has been added as a new clinical site in the ongoing Phase 1 trial of the Company’s INB-100, a donor-derived allogeneic gamma-delta T cell therapy for patients with leukemias undergoing haploidentical stem cell transplantation. The addition of this leadin...

October 29, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletio...

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted approach that potentially allows for safer deep B cell depletion.INB-619 is the first pan-gamma delta (γδ) T cell engager designed to significantly expand multiple γδ T cell subsets for efficient, durable target elimination.INB-619 achieved robust γδ T cell expansion and complete B cell depletion...

October 27, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Reports Second Quarter 2025 Financial Results and Recent Busine...

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient remaining progression-free for over four years.Received the Host Region USA East Abstract Award at ISCT 2025 for IN8bio’s DeltEx™ manufacturing platform.Presented preclinical data at ASGCT 2025 on INB-619, a novel gamma-delta T cell engager, and its ability to induce pan-gamma-delta T cell expansion and target CD19+ B c...

August 7, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Trea...

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of INB-200 for newly-diagnosed GBM has recen...

June 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch